Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy
Frontiers in Public Health · 17.04.2024 · 12
DOI: 10.3389/fpubh.2024.1364664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 17.04.2024. Verfasst von Friedhelm Sayk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Division of Gastroenterology and Nephrology, University Hospital Schleswig-Holstein, Lübeck, Germany. Hauptthemen laut MEDLINE: Shiga-Toxigenic Escherichia coli, Escherichia coli Infections, Azithromycin, Anti-Bacterial Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Asymptomatic long-term carriers of Shigatoxin producing Escherichia coli (STEC) are regarded as potential source of STEC-transmission. The prevention of outbreaks via onward spread of STEC is a public health priority. Accordingly, health authorities are imposing far-reaching restrictions on asymptomatic STEC carriers in many countries. Various STEC strains may cause severe hemorrhagic colitis complicated by life-threatening hemolytic uremic syndrome (HUS), while many endemic strains have never been associated with HUS. Even though antibiotics are generally discouraged in acute diarrheal STEC infection, decolonization with short-course azithromycin appears effective and safe in long-term shedders of various pathogenic strains. However, most endemic STEC-strains have a low pathogenicity and would most likely neither warrant antibiotic decolonization therapy nor justify social exclusion policies. A risk-adapted individualized strategy might strongly attenuate the socio-economic burden and has recently been proposed by national health authorities in some European countries. This, however, mandates clarification of strain-specific pathogenicity, of the risk of human-to-human infection as well as scientific evidence of social restrictions. Moreover, placebo-controlled prospective interventions on efficacy and safety of, e.g., azithromycin for decolonization in asymptomatic long-term STEC-carriers are reasonable. In the present community case study, we report new observations in long-term shedding of various STEC strains and review the current evidence in favor of risk-adjusted concepts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine I, Division of Gastroenterology and Nephrology, University Hospital Schleswig-Holstein, Lübeck, Germany.
- Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, Lübeck, Germany.
- Institute for Medical Microbiology, Virology and Hygiene, Department for Infection Prevention and Control, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Zitieren
APA
Sayk, F., Hauswaldt, S., Knobloch, J. K., Rupp, J., & Nitschke, M. (2024). Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1364664
Vancouver
Sayk F, Hauswaldt S, Knobloch JK, Rupp J, Nitschke M. Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy. Frontiers in Public Health. 2024;12. doi:10.3389/fpubh.2024.1364664
BibTeX
@article{Sayk2024,
author = {Sayk, Friedhelm and Hauswaldt, Susanne and Knobloch, Johannes K and Rupp, Jan and Nitschke, Martin},
title = {Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy},
journal = {Frontiers in Public Health},
year = {2024},
volume = {12},
doi = {10.3389/fpubh.2024.1364664}
}
EUVIMED